INTRODUCTION

Cancer-related death accounts for the majority of deaths among humans in both the developing and developed world. It is estimated that by 2020, in the United States, there will be 1,806,590 new cancer cases and 606,520 cancer deaths. At present, the primary treatment method for most solid cancers is removing the tumour during surgery. Unfortunately, the surgery process causes a large number of tumour cells to be released, reducing the activity of T, B and NK lymphocytes in the postoperative period, which possibly leads to tumour progression. Anaesthetic agents may play an essential role in tumour relapse and metastasis because they are administered at the moment of greatest risk of transmission: surgical removal of the tumour. Recently, many studies have uncovered that the choice of anaesthetic agent could influence the prognosis of cancer patients undergoing cancer surgery.

Propofol (2,6-diisopropylphenol) is currently one of the most commonly used anaesthetics in clinical practice. It was first introduced into clinical treatment in 1986 and initially served just as an anaesthetic inducer during surgery. However, it soon became one of the most extensively used intravenous anaesthetic agents to produce sedative and anaesthetic effects. Notably, propofol not only served as a sedative or hypnotic drug during surgery but was also shown to have many non-anaesthetic effects, such as anti-tumour or carcinogenic activity, in recent investigations. In this review, we discuss the effects of propofol on the biological behaviour of cancer and the mechanisms of its biological function in vitro via regulating multiple signalling pathways, downstream molecules, microRNAs and long non-coding RNAs. Emerging evidence has indicated that propofol can enhance the anti-tumour effect of chemotherapeutic drugs or some small molecular compounds. Additionally, in vivo animal models have shown that propofol inhibits tumour growth and metastasis. Furthermore, most clinical trials indicate that propofol is associated with better survival outcomes in cancer patients after surgery. Propofol use is encouraged in cancers that appear to have a better prognosis after its use during surgery. We hope that future large and prospective multicenter studies will provide more precise answers to guide the choice of anaesthetics during cancer surgery.
2 ROLE OF PROPOFOL IN CANCER CELLS

2.1 Biological behaviour of propofol in cancer cells

Propofol is a popular anaesthetic agent with potent anti-tumour activity. However, a few studies showed that propofol promoted cell proliferation and invasion in gallbladder cancer and breast cancer.17,18 Nevertheless, a large body of literature reports that propofol inhibits the metastasis of cancer cells in colon cancer, breast cancer, lung adenocarcinoma, hepatocellular carcinoma and cervical cancer.19-23 Mechanistically, a research group used atomic force microscopy and found that propofol disrupted the cellular cytoskeleton of cervical cancer, which found possibly unveiled the biological mechanism of how propofol reduced migration ability.23 A study reported that propofol exerted an inhibitory effect on tumorigenesis by promoting autphagic flux and triggering autophagosome accumulation in cervical cancer cells.24 Propofol not only inhibited the adhesion and migration of breast cancer cells but also promoted apoptosis.25 In oesophageal squamous cancer cells, propofol induced cell apoptosis and reduced proliferation, invasion, and angiogenesis in a dose- and time-dependent manner.26 These laboratory data provide support for the tumour-suppressive effects of propofol in multiple cancers.

Moreover, propofol may play a pivotal role in affecting the tumour microenvironment of the serum in patients undergoing surgery. Recent data showed that in patients undergoing radical resection of non-small cell lung cancer (NSCLC), the serum of patients treated with propofol had a lower concentration of tumour angiogenesis-related factors, such as vascular endothelial growth factor (VEGF) and transforming growth factor beta, than that in the sevoflurane group.27 Serum of breast cancer patients who were given propofol or sevoflurane during surgery was added to oestrogen receptor (ER)-negative breast cancer cells, and it was found that more breast cancer cells treated with serum from patients who received propofol underwent apoptosis than those treated with serum from patients who received sevoflurane.28 Similarly, serum from colon cancer patients who received propofol during surgery inhibited colon cancer cell proliferation and invasion, and promoted apoptosis in vitro when compared with cells treated using serum from patients who received sevoflurane.29 These phenomena indicate that propofol may affect the tumour microenvironment of the serum, thereby playing an inhibitory role in the development and progression of cancer.

2.2 Effect of propofol on cancer cells by regulating related signalling pathways or downstream molecules

To elucidate the molecular mechanism of the influence of propofol on the biological behaviours of cancer cells, we reviewed a large amount of literature about the regulation of signalling pathways or downstream molecules related to cancer cell proliferation, apoptosis, migration and invasion after propofol stimulation (Table 1; Figure 1). A few studies showed that propofol promoted cell proliferation and invasion in gallbladder cancer in a dose-dependent and time-dependent manner by activating the nuclear factor E2-related factor-2 (Nrf2) at the transcriptional and translational level.31 In accordance with this, propofol induced cell migration by activating the Nrf2 signalling pathway and triggering cell proliferation in part via downregulation of the expression of p53 in human breast cancer MDA-MB-231 cells.18 Nonetheless, plenty of studies have shown the opposite results. For example, an in vitro study found that propofol suppressed colon cancer cell invasion partly via extracellular signal-regulated kinases 1 and 2 (ERK1/2)-dependent downregulation of matrix metalloproteinases (MMPs).19 Additionally, to clarify the molecular mechanism in metastatic inhibitory effects of propofol in breast cancer, Li et al20 reported that propofol reduced MMP expression via the suppression of nuclear factor-kappa B (NF-kB) pathways and inhibited the invasion and migration ability of cancer cells. In cervical cancer, propofol suppressed cell viability and induced apoptosis by inhibiting of the mammalian target of rapamycin (mTOR)/p70 ribosomal protein S6 kinase (p70S6K) pathway.30 In glioma cells, propofol inhibited cell growth and increased cell apoptosis by downregulating wingless and proto-oncogene integration-1 (Wnt) signalling.31 In NSCLC, cell viability was reduced and cell apoptosis was promoted by an increase the activity of the ERK1/2-dependent PUMA signalling pathway following exposure to propofol.32 In cholangiocarcinoma cells, propofol exerted inhibitory effects on metastasis and induced apoptosis. Furthermore, the level of B-cell lymphoma-2-associated X (Bax) expression was increased and B-cell lymphoma-2 (Bcl-2) expression was decreased after adding propofol; the Wnt/Ji-catenin signalling pathway was inhibited as the concentration of propofol increased.33 In Leydig cell cancer, propofol induced the apoptosis of cells via promoting the activity of caspase, as well as inhibiting the protein kinase B (Akt) pathway.34 One study illustrated that propofol inhibited the process of glycolysis and repressed hypoxia-inducible factor 1α (HIF-1α) in colorectal cancer cells via inhibition of the NMDAR-calcium/calmodulin-dependent protein kinase II-ERK pathway, which might be related to the inhibition of cancer progression.35 Chen et al36 found that propofol might promote cancer cell growth and metastasis via blocking the Wnt/Ji-catenin and NF-kB pathways in an ANRIL-dependent method in papillary thyroid cancer. Consistent with the previous findings, propofol inhibited the maintenance and self-renewal of leukaemia stem cells by suppressing Akt/mTOR and Wnt/Ji-catenin.37 The growth and activity of gastric cancer cells were inhibited by the upregulated expression of the inhibitor of growth 3 (ING3) following treatment with propofol, and ING3 exerted an important role in propofol-induced anti-tumour effects.38 Notably, propofol inhibited cell proliferation and promoted apoptosis in a dose- and time-dependent manner by upregulating Forkhead Box O1 (FoxO1) expression in oral squamous cell carcinoma. Furthermore, the activity of FoxO1 could be increased at the transcriptional level by binding to the promoter of Growth Arrest Specific 5 after treatment with propofol, thereby enhancing the anti-tumour effects of propofol.39 In addition, under exposure to propofol, the proliferation, migration and invasion of endometrial cancer
3 of 11

XU et al.

cells were suppressed due to the downregulated expression of SRY-box transcription factor 4 (Sox4).40 Using cardi cell cell lines, Su et al41 reported that propofol suppressed cell proliferation and induced cell apoptosis, which might be partially associated with the inhibition of the mitogen-activated protein kinase/ERK signalling pathway. Consistently, propofol elevated the expression of apoptosis-related proteins such as Caspase-3, Bax and phosphorylated ERK1/2 in cardia cancer cells. Thus, a number of investigations have uncovered that propofol has inhibitory effects on different cancer cells through various cellular pathways.

2.3 Anti-tumour effect of propofol in cancer cells via regulation of microRNAs

It has been revealed that miRNAs, endogenous non-coding small RNA molecules, play pivotal roles in affecting gene expression, signaling pathways and cellular biological effects, such as proliferation, metastasis and apoptosis.42 Numerous studies have revealed that the effects of propofol in human cancer might be regulated by miRNA expression.

The expression of miRNAs is elevated after adding propofol, which has tumour-suppressive action against cancer cells (Table 2; Figure 2). For instance, propofol significantly inhibited epithelial ovarian cancer cell proliferation and promoted apoptosis partly via the upregulation of miR-let-7i expression.43 In addition, under propofol exposure, the proliferation and invasion of pancreatic cancer cells were effectively inhibited, and apoptosis was triggered in part by the increased expression of miR-133a.44 Using human hepatocellular carcinoma (HCC) cell lines, Gong et al45 reported that propofol inhibited the proliferation, invasion and migration of cells by increasing the expression of miR-219-5p, and subsequently attenuated the activation of the Wnt/β-catenin signalling pathway. Propofol

| TABLE 1 The biological function of propofol in cancer cell by regulation signalling pathways or downstream molecules |
| --- |
| The role of propofol in oncogenesis | Cancer types | Signalling pathways regulated by propofol | Function | Ref. |
| --- |
| Promotes oncogenesis | Gallbladder cancer | Activates Nrf2 | Induces cells proliferation and invasion | 17 |
| Breast cancer | Activates Nrf2 and downregulates p53 | Induces cells migration and proliferation | 18 |
| Suppresses oncogenesis | Colon cancer | Downregulates MMPs | Inhibits cells invasion | 19 |
| Breast cancer | Downregulates MMPs via suppression of NF-κB pathways | Inhibits cells invasion and migration | 20 |
| Cervical cancer | Downregulates mTOR/p70S6K | Inhibits cells viability and induces apoptosis | 30 |
| Glioma | Downregulates Wnt pathway | Inhibits cells growth and induces apoptosis | 31 |
| Non-small cell lung cancer | Activates ERK1/2-dependent PUMA pathway | Inhibits cells viability and induces apoptosis | 32 |
| Cholangiocarcinoma | Downregulates Bcl-2, upregulates Bax and inhibits Wnt/β-catenin pathway | Inhibits cells metastasis and apoptosis | 33 |
| Leydig cell cancer | Activates caspase and inhibits Akt pathway | Induces apoptosis | 34 |
| Colorectal cancer | Inhibits NMDAR-CAMKII-ERK pathway | Inhibits cells glycosylation and cancer progression | 35 |
| Thyroid cancer | Blocks Wnt/β-catenin and NF-κB pathways | Promotes cells growth and metastasis | 36 |
| Leukaemia stem cell | Suppresses Akt/mTOR and Wnt/β-catenin | Inhibits cells self-renewal | 37 |
| Gastric cancer | Upregulates ING3 | Induces anti-tumour effects | 38 |
| Oral squamous cell carcinoma | Upregulates FoxO1 | Inhibits cells proliferation and induces apoptosis | 39 |
| Endometrial cancer | Downregulates Sox4 | Inhibits cells proliferation, migration and invasion | 40 |
| Cardia cancer | Inhibits MAPK/ERK signalling pathway | Inhibits cells proliferation and induces apoptosis | 41 |

Abbreviations: Akt, protein kinase B; Bax, B-cell lymphoma-2 associated X; Bcl-2, B-cell lymphoma-2; CAMKII, calcium/calmodulin-dependent protein kinase II; ERK1/2, extracellular signal-regulated kinases 1 and 2; FoxO1, Forkhead Box O1; ING3, inhibitor of growth 3; MAPK, mitogen-activated protein kinase; MMP, matrix metalloproteinase; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor-kappa B; NMDAR, N-methyl-D-aspartate receptor; Nrf2, nuclear factor E2-related factor-2; p53, Tumour Protein P53; p70S6K, p70 ribosomal protein S6 kinase; Sox4, SRY-box transcription factor 4; Wnt, wingless and proto-oncogene integration-1.
significantly suppressed osteosarcoma cell proliferation and invasion, and induced apoptosis, in part due to the decreased expression of MMP-13 through elevated miR-143 expression. In ovarian cancer, propofol inhibited cell invasion and proliferation via upregulating the expression of miR-9 and suppressing the activity of NF-κB signaling pathway. In gastric cancer, propofol has been found to inhibit cell proliferation, migration and invasion by upregulating miR-195 and subsequent attenuation of the activity of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) and NF-κB pathways. Similarly, another study displayed that propofol gradually attenuated gastric cancer cell proliferation, migration and invasion in a time- and dose-dependent manner, which was in line with findings from the previous studies mentioned above. It is worth noting that propofol exerted these anti-tumour effects in gastric cancer cells by upregulating miR-195 and subsequent attenuation of the activity of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) and NF-κB pathways. Additionally, another study displayed that propofol gradually attenuated gastric cancer cell proliferation, migration and invasion in a time- and dose-dependent manner, which was in line with findings from the previous studies mentioned above. It is worth noting that propofol exerted these anti-tumour effects in gastric cancer cells by upregulating miR-195 and subsequent attenuation of the activity of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) and NF-κB pathways. Another essential result of the study was that the inhibitory anti-tumour effects of propofol on colorectal cancer cells could be reversed by suppressing miR-124-3p.1 expression or the overexpression of AKT3. A large number of miRNAs act as a driving force in the progression of cancer and their expression levels decrease after adding propofol to cancer cells, which may explain the anti-tumour effects of propofol (Table 2; Figure 3). For example, propofol contributed to inhibiting cell viability, migration, and invasion, and promoting apoptosis by downregulating miR-374a and then inhibiting the Wnt/β-catenin and phosphoinositide 3-kinase (PI3K)/AKT pathways in HCC. Similarly, propofol inhibited the proliferation and invasion of gastric cancer cells, and promoted apoptosis partly via decreased expression of miR-24-3p.1 and decreasing that of its target gene, AKT3. Another recent study found that under propofol treatment, the number of apoptotic cells was increased via inhibition of the miR-24/cyclin-dependent kinase inhibitor 1B.
Moreover, it has been pointed out that propofol attenuated cell proliferation and EMT by downregulating miR-21 expression and then inactivating the PI3K/AKT and Wnt/β-catenin pathways in breast cancer. Sun et al. reported that propofol inhibited NSCLC cell growth, migration and invasion by downregulating miR-372 expression and subsequently suppressed the activity of the Wnt/β-catenin and mTOR pathways.

### TABLE 2  The biological function of propofol in cancer cell by regulation of miRNA or lncRNA

| miRNA/IncRNA       | Cancer types          | miRNA or IncRNA regulated by propofol          | Downstream gene regulated by miRNA or IncRNA | Functions                                                                 | Ref. |
|--------------------|-----------------------|-----------------------------------------------|---------------------------------------------|---------------------------------------------------------------------------|------|
| miRNA              | Epithelial ovarian cancer | Upregulates miR-let-7i                        | /                                          | Inhibits cells proliferation and induces apoptosis                        | 43   |
|                    | Pancreatic cancer      | Upregulates miR-133a                         | /                                          | Inhibits cells proliferation and invasion                                 | 44   |
|                    | Hepatocellular carcinoma | Upregulates miR-219-5p                      | Inactivates Wnt/β-catenin signalling pathway | Inhibits cells proliferation and metastasis                               | 45   |
|                    | Osteosarcoma           | Upregulates miR-143                         | Downregulates MMP-13                       | Inhibits cells proliferation and invasion                                  | 46   |
|                    | Ovarian cancer         | Upregulates miR-9                           | Downregulates NF-κB signalling pathway     | Inhibits cells invasion and proliferation                                 | 47   |
|                    | Gastric cancer         | Upregulates miR-195, miR-29 family and miR-140-5p | Downregulates JAK/STAT, NF-κB pathways, MMP-2, MMP-9 and Bcl-2; Upregulates cleaved caspase-3 | Inhibits the cell proliferation, migration and invasion; induces cell apoptosis | 48-50|
|                    | Non-small cell lung cancer | Upregulates miR-486 and miR-1284         | Upregulates E-cadherin; downregulates N-cadherin, vimentin and Snail | Inhibits the cell proliferation, metastasis and epithelial-mesenchymal transition process; promotes apoptosis | 51,55|
|                    | Pancreatic cancer      | Upregulates miR-328                         | /                                          | Inhibits cells growth and metastasis                                      | 53   |
|                    | Colorectal cancer      | Upregulates miR-124-3p.1                    | Downregulates AKT3                        | Inhibits cells proliferation and metastasis                               | 54   |
|                    | Hepatocellular carcinoma | Downregulates miR-374a                     | Inhibits Wnt/β-catenin and PI3K/ AKT pathways | Inhibits cell viability, migration and invasion; promotes apoptosis       | 55   |
|                    | Gastric cancer         | Downregulates miR-221                        | /                                          | Inhibits the proliferation and invasion; promotes apoptosis               | 56   |
|                    | Pancreatic cancer      | Downregulates miR-21                        | Inhibits Slug pathway; increases PUMA and E-cadherin | Inhibits cell growth and invasion                                        | 57   |
|                    | Breast cancer          | Downregulates miR-21 and miR-24             | Inactivates PI3K/AKT, Wnt/β-catenin and p27 | Inhibits cells proliferation and EMT; promotes apoptosis                 | 58,59|
|                    | Non-small cell lung cancer | Downregulates miR-372                     | Inactivates Wnt/β-catenin and mTOR signalling pathways | Inhibits cells growth, migration and invasion                             | 60   |
|                    | Hepatocellular carcinoma | Downregulates miR-142-3p                   | Downregulates RAC1                        | Inhibits cells metastasis                                                | 62   |
| IncRNA             | Colon cancer           | Downregulates HOTAIR                       | Inactivates Wnt signalling pathway         | Inhibits cell metastasis and promotes cell apoptosis                     | 65   |
|                    | Colorectal cancer      | Downregulates HOXA11-AS                     | Upregulates miR-let-7i                    | Promotes cell apoptosis                                                  | 66   |
|                    | Gastric cancer         | Downregulates MALAT1                       | Downregulates ATG5                        | Promotes cell apoptosis and reduces chemoresistance                      | 67   |

Abbreviations: AKT, protein kinase B; ATG5, autophagy-related genes 5; Bcl-2, B-cell lymphoma-2; HOTAIR, HOX antisense intergenic RNA; HOXA11-AS, HOXA11 Antisense RNA; JAK, Janus kinase; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MMP, matrix metalloproteinase; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor-kappa B; p27, cyclin-dependent kinase inhibitor 1B; PI3K, phosphoinositide 3-kinase; RAC1, Ras-related C3 botulinum toxin substrate 1; STAT, signal transducer and activator of transcription 3; Wnt, wingless and proto-oncogene integration-1.
A recent study discovered that microvesicles were able to shuttle miRNAs into nearby or distant cells and then regulate the expression of target genes. \(^61\) Zhang et al.\(^62\) showed that propofol triggered the shutting of miR-142-3p from macrophages to HCC cells, which decreased the expression of Ras-related C3 botulinum toxin substrate 1 (RAC1) and then inhibited the metastasis of HCC cells. Furthermore, extracellular vesicles and their microRNA cargo are important promoters of malignant cell communication and mediate the effects of anaesthetics on tumour biology during colorectal cancer surgery. Buschmann et al.\(^63\) found that propofol influenced microRNA profiles in extracellular vesicles in serum samples and affected the signal pathways involved in the inhibitory effect of proliferation and metastasis in colorectal cancer patients receiving surgery.

Taken together, these investigations revealed that propofol contributes to triggering anti-tumour activity by downregulating or up-regulating miRNA expression and can be used as a treatment agent in various cancers.

2.4 | Effect of propofol on cancer cells due to the regulation of long non-coding RNAs

LncRNAs are longer than 200 nucleotides but are unable to express proteins. It was emphasized that lncRNAs play an essential role in the occurrence and progression of cancer.\(^64\) One study revealed that propofol decreased colon cancer cell metastasis and increased
cell apoptosis in part through the inhibition of IncRNA HOX antisense intergenic RNA expression (HOTAIR) and subsequent inactivation of the Wnt signalling pathway. The potential mechanism of propofol in colorectal cancer is the suppression of tumorigenesis by downregulating a highly conserved IncRNA HOXA11 Antisense RNA (HOXA11-AS) and upregulating miR-let-7i, and then promoting cell apoptosis. Additionally, propofol also plays an essential role in regulating autophagy. To date, autophagy has been found to play a dual role in the development of cancer dependent on a variety of factors including the tumour microenvironment, cancer type and stage and genetic background. In the early stages of tumorigenesis, autophagy acted as a tumour suppressor, which prevented tumour initiation, proliferation, invasion and metastasis. However, once the tumours progress to the late stage, autophagy promoted tumorigenesis by sustaining tumour metabolism, growth, survival, and facilitating metastasis and resistance to therapeutic agents. In gastric cancer cells, propofol facilitated apoptosis and reduced autophagy-related chemoresistance to cisplatin via inhibition of IncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1). Mechanically, it has been demonstrated that the level of MALAT1 was lower and miR-30e was upregulated, which caused suppression of autophagy-related genes 5 (ATG5), and subsequently inactivated autophagy-related chemoresistance in gastric cancer cells following propofol treatment. These investigations have shown that propofol exerted tumour-inhibitory effects by regulating IncRNA expression (Table 2; Figure 3).

### 2.5 Effect of propofol in combination with chemotherapeutic drugs or molecular compounds in cancer cells

Recently, more studies have found that the combination of propofol and chemotherapeutic agents or some molecular compounds may play anti-tumour roles in human cancer (Table 3). For instance, propofol enhanced the chemosensitivity to cisplatin-induced apoptosis in cervical cancer cells through the epidermal growth factor receptor (EGFR)/JAK2/STAT3 pathway. In ovarian cancer cells, treatment with propofol and cisplatin promoted cell apoptosis by elevating the activity of the FOXO1 pathway. Consistent with this study, all paclitaxel-sensitive and paclitaxel-resistant cells underwent paclitaxel-induced apoptosis via decreased expression of the Slug protein under treatment with propofol in ovarian cancer. A further study found that propofol reduced the upregulation of the NF-κB signalling pathway induced by gemcitabine, thereby promoting the chemosensitivity of pancreatic cancer cells to gemcitabine. Additionally, it was widely accepted that hypoxia is a common phenomenon in tumour development and related to the EMT process and cancer progression. Propofol reversed the drug resistance of docetaxel induced by hypoxia and attenuated the process of EMT via inhibition of HIF-1α in prostate cancer cells, suggesting that propofol may help overcome prostate cancer’s resistance to chemotherapy under hypoxic conditions. In addition, propofol effectively inhibited lipopolysaccharide (LPS)-induced EMT and migration in NSCLC cells. Consistently, propofol suppressed the invasion of NSCLC cells by downregulating the expression of HIF-1α in LPS-stimulated NSCLC cells.

Herein, the significantly suppressive role of propofol in combination with chemotherapeutic drugs or molecular compounds was observed in propofol-treated cancer cells, supporting the anti-tumour activity of propofol.

### 3 EFFECT OF PROPOFOL ON ANIMAL MODELS OF CANCER

Various investigations have discovered that propofol has essential anticancer properties not only in vitro but also in vivo. A large number of studies indicated that in nude mouse models, propofol inhibited the growth of xenograft tumours in numerous cancers such as cervical cancer, lung cancer and pancreatic cancer. The latter results appear to be consistent with previous studies that found propofol decreased the growth of endometrial cancer in a xenograft tumour model, but the effect was abolished by increased expression of Sox4. Xu et al demonstrated that propofol decreased the growth of tumour and inhibited the Wnt signalling pathway by inhibiting the expression of Wnt target genes (such as AXIN2, CCND1 and

| Chemotherapy drugs or molecular compounds | Cancer types | Downstream gene regulated by propofol | Functions | Ref. |
|------------------------------------------|-------------|-------------------------------------|-----------|-----|
| Cisplatin                                | Cervical cancer | EGFR/JAK2/STAT3 pathway | Enhances the chemosensitivity | 75 |
| Cisplatin                                | Ovarian cancer | Activates FOXO1 | Promotes cell apoptosis | 76 |
| Paclitaxel                               | Ovarian cancer | Downregulates Slug | Promotes cell apoptosis | 77 |
| Gemcitabine                              | Pancreatic cancer | Downregulates NF-κB signalling pathway | Enhances the chemosensitivity | 78 |
| Docetaxel                                | Prostate cancer | Downregulates HIF-1α | Enhances the chemosensitivity | 80 |
| LPS                                      | Non-small cell lung cancer | Downregulates HIF-1α | Inhibits EMT, migration and invasion | 81 |

Abbreviations: EGFR, epidermal growth factor receptor; EMT, epithelial-mesenchymal transition; FOXO1, Forkhead Box O1; HIF-1α, hypoxia-inducible factor-1α; JAK2, Janus kinase 2; LPS, lipopolysaccharide; NF-κB, nuclear factor-kappa B; STAT3, signal transducer and activator of transcription 3.
BCL2) in glioma. In addition, the growth and volume of tumour in mice decreased remarkably under treatment with propofol in colorectal cancer, but the inhibitory effect could be reversed by rapastinel, an agonist of the N-methyl-D-aspartate (NMDA) receptor.35 Combining cisplatin and propofol, Zhang et al84 demonstrated that the size and weight of the gastric cancer xenograft model were significantly decreased compared with that of the control group, which indicated that propofol increased the chemosensitivity of gastric cancer to cisplatin. Furthermore, under propofol and cisplatin treatment, the inhibitory effect on tumour growth of gastric cancer xenograft was strengthened by downregulation of MALAT1 and ATG5 expression, which might be partly achieved via inhibition of autophagy. In a recent study, propofol anaesthesia or sevoflurane anaesthesia was used for breast cancer resection in an orthotopic mouse model. It was found that the propofol treatment group had lesser lung metastasis than the sevoflurane group 2 weeks after surgery.84 Another important result of the study was that the IL-6 and VEGF serum levels were significantly lower in the propofol group than in the sevoflurane group.84 Consistent with in vitro studies, results of these explorations in vivo also suggest that propofol exerts an inhibitory effect on tumour growth and metastasis, as well as facilitates the sensitivity of tumours to cisplatin.

4 | EFFECT OF PROPOFOL ON THE PROGNOSIS OF PATIENTS WITH CANCER

A number of clinical investigations found that propofol has no effect on prognosis in several cancers (Table 4). A number of retrospective studies have indicated that propofol did not influence survival outcomes in other types of cancer following surgery. For example, in a retrospective cohort study, there was no difference in mortality or locoregional recurrence rate in a 5-year follow-up after treatment with desflurane or propofol during breast cancer surgery.11 Consistent with previous investigations, Cata et al12 reached the conclusion that propofol was not a protective factor for cancer recurrence during breast cancer surgery relative to sevoflurane anaesthesia. In NSCLC, a retrospective study revealed that there was no difference between the propofol group and the inhalation group for overall survival (OS) or relapse-free survival (RFS) during lung cancer surgery.13 Recently, one study found that in patients with high-grade glioma undergoing cancer surgery, intraoperative use of propofol or sevoflurane anaesthesia led to no difference in OS or progression-free survival (PFS).14 In the study by Oh et al,15 among patients who underwent gastric cancer surgery, there was no difference in cancer-related mortality after using propofol or inhalation anaesthesia. Nonetheless, these findings are retrospective and have some important limitations. Recently, consistent with previous studies, a randomized controlled trial including more than 2000 women undergoing breast cancer surgery reported that breast cancer recurrence did not reduce in paravertebral blocks or in the propofol group compared with the volatile anaesthetic and opioids for analgesia groups.16 These results have demonstrated that the prognosis of these cancer patients undergoing cancer surgery is no different than the prognosis of those using other volatile anaesthetics.

However, many studies, including retrospective investigations and prospective trials, have evaluated the relationship between propofol and prognosis thus far and concluded that propofol treatment can improve survival in many cancer patients (Table 4). In oesophageal cancer, a retrospective investigation showed that treatment with propofol during surgery was related to better 1-, 3- and 5-year OS rates and RFS in comparison with the use of volatile anaesthetic agents (including isoflurane, sevoflurane and desflurane).4 Similarly, a retrospective study included a total of 2856 patients who received gastric cancer resection surgery and found that the OS of the patients in the propofol group was better than that of the sevoflurane group.5 Colon cancer patients treated with propofol exhibited a favourable OS and disease-free survival (DFS) and less postoperative metastasis than those who were treated with desflurane during surgery.6 Compared with desflurane, propofol was associated with

| Type of study | Cancer types | Volatile anaesthesia | Outcomes | Ref. |
|---------------|--------------|----------------------|----------|-----|
| Retrospective | Breast cancer | Desflurane or sevoflurane | No difference | 11,12 |
| Retrospective | Non-small cell lung cancer | Sevoflurane | No difference | 13 |
| Retrospective | High-grade glioma | Sevoflurane | No difference | 14 |
| Retrospective | Gastric cancer | Desflurane or sevoflurane | No difference | 15 |
| Prospective | Breast cancer | Sevoflurane | No difference | 16 |
| Retrospective | Oesophageal cancer | Isoflurane, sevoflurane or desflurane | Better OS and RFS | 4 |
| Retrospective | Gastric cancer | Sevoflurane | Better OS | 5 |
| Retrospective | Colon cancer | Desflurane | Better OS and DFS; less postoperative metastasis | 6 |
| Retrospective | Hepatocellular carcinoma | Desflurane | Better OS | 7 |
| Retrospective | Cholangiocarcinoma | Desflurane | Better survival and less postoperative metastases | 8 |
| Prospective | Bladder cancer | Sevoflurane | Longer DFS | 2 |

Abbreviations: DFS, disease-free survival; OS, overall survival; RFS, recurrence-free survival.
better OS when used in hepatectomy for HCC. Moreover, patients with HCC had lower cancer-specific mortality, and less distant metastasis and local recurrence in the propofol group than in the desflurane group. Consistent with those results, propofol anaesthesia was related to better survival and less postoperative metastases in comparison with desflurane anaesthesia in open intrahepatic cholangiocarcinoma surgery. Notably, a meta-analysis study including 7866 patients with different types of cancer discovered that the use of propofol improved the OS and RFS of cancer in comparison with the use of inhalational anaesthesia. Additionally, another retrospective cohort study found that propofol anaesthesia was related to better OS and a lower postoperative biochemical recurrence rate than those with desflurane anaesthesia in patients undergoing robot-assisted radical prostatectomy. However, these previous studies have the limitations of most retrospective investigations. Hence, a prospective trial was warranted to evaluate the effect of propofol on bladder cancer outcomes. There were 100 patients who underwent radical cystectomy, and it was found that patients treated with the combination of propofol and epidural anaesthesia had a longer DFS than patients who were treated with sevoflurane combined with opioids. There is growing evidence suggesting that volatile anaesthesia may contribute to poor survival outcomes, whereas propofol seems to provide better survival outcomes in cancer patients undergoing tumour removal surgery.

A series of studies have shown that the different influences of propofol on oncogenic outcomes might depend on the primary site of cancer. However, most studies still show that propofol contributes to a better prognosis. It is encouraged to use propofol in cancers that appear to have a better prognosis after using propofol during the surgery. For cancers in which the prognosis was not influenced by propofol, prospective multicenter studies with larger sample sizes are currently underway, which are expected to provide clear answers.

5 | CONCLUSION

In summary, the role of propofol in the progression of cancer patients is relatively consistent across a large number of laboratory researches and clinical investigations. Only a few results suggest that propofol increases cell proliferation in certain cancer types and several clinical trials indicated that propofol has no influence on the prognosis of cancer patients. However, most in vitro studies suggest that propofol inhibits most tumour cell proliferation, migration and invasion, and promotes cell apoptosis by regulating many signalling pathways and non-coding mRNA expression. Consistent with this, numerous in vivo studies indicated that propofol suppresses tumour growth and metastasis. Additionally, a large body of literature has indicated that propofol is associated with better survival outcomes in cancer patients after surgery relative to the use of volatile anaesthetics. Propofol also exerts significant effects in increasing the sensitivity to chemotherapeutic drugs.

Therefore, it is critical to elucidate how to choose the most suitable anaesthetic agents for different types of cancer to obtain the best prognosis for cancer patients. Propofol use is encouraged in cancers that appear to have a better prognosis after its use during the surgery. For cancers in which the prognosis was not influenced by propofol, further animal trials and prospective clinical studies are needed to understand the effects that the type of anaesthesia has on the development of cancer and provide us with more precise answers to guide the choice of anaesthetics during cancer surgery.

ACKNOWLEDGMENTS

This work was supported by a grant from Gynecology and obstetrics of combined traditional Chinese and Western Medicine of Zhejiang Province (2017-XK-A42).

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

AUTHOR CONTRIBUTIONS

YX, WJ and XZ conceptualized and design the manuscript. YX and SP searched the literature and wrote the manuscript. FX, WJ and XZ critically viewed, edited and approved the manuscript. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Xueqiong Zhu https://orcid.org/0000-0002-8389-928X

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.
2. Guerrero Orriach JL, Raigon Ponferrada A, Malo Manso A, et al. Anesthesia in combination with propofol increases disease-free survival in bladder cancer patients who undergo radical tumor cystectomy as compared to inhalational anesthetics and opioid-based analgesia. Oncology. 2020;98(3):161-167.
3. Kurosawa S. Anesthesia in patients with cancer disorders. Curr Opin Oncology. 2012;24:3:376-384.
4. Jun I-J, Jo J-Y, Kim J-I, et al. Impact of anesthetic agents on overall and recurrence-free survival in patients undergoing esophageal cancer surgery: a retrospective observational study. Sci Rep. 2017;7(1):14020.
5. Zheng X, Wang Y, Dong L, et al. Effects of propofol-based total intravenous anesthesia on gastric cancer: a retrospective study. Onco Targets Ther. 2018;11:1141-1148.
6. Wu Z-F, Lee M-S, Wong C-S, et al. Propofol-based total intravenous anesthesia is associated with better survival than desflurane anesthesia in colon cancer surgery. Anesthesiology. 2018;129(5):932-941.
7. Lai H-C, Lee M-S, Lin C, et al. Propofol-based total intravenous anesthesia is associated with better survival than desflurane anesthesia in hepatectomy for hepatocellular carcinoma: a retrospective cohort study. Br J Anaesth. 2019;123(2):151-160.
8. Lai H-C, Lee M-S, Lin K-T, et al. Propofol-based total intravenous anesthesia is associated with better survival than desflurane
anesthesia in intrahepatic cholangiocarcinoma surgery. Medicine. 2019;98(51):e18472.
9. Yap A, Lopez-Olivo MA, Dubowitz J, Hiller J, Riedel B. Global Onco-Anesthesia Research Collaboration G. Anesthetic technique and cancer outcomes: a meta-analysis of total intravenous versus volatile anesthesia. Can J Anaesth. 2019;66(5):546-561.
10. Sahinovic MM, Struys M, Absalom AR. Clinical pharmacokinetics and pharmacodynamics of propofol. Clin Pharmacokinet. 2018;57(12):1539-1558.
11. Huang Y-H, Lee M-S, Lou Y-S, et al. Propofol-based total intravenous anesthesia for breast cancer surgery. PLoS ONE. 2019;14(11):e0224728.
12. Cata JP, Forget P. Paravertebral block with propofol anaesthesia does not improve survival compared with sevoflurane anaesthesia for breast cancer surgery: independent discussion of a randomised controlled trial. Br J Anaesth. 2020;124(1):19-24.
13. Oh TK, Kim K, Jheon S, et al. Long-term oncologic outcomes for patients undergoing volatile versus intravenous anesthesia for non-small cell lung cancer surgery: a retrospective propensity matching analysis. Cancer Control. 2018;25(1):1073274818775360.
14. Dong J, Zeng M, Ji N, et al. Impact of anesthesia on long-term outcomes in patients with supratentorial high-grade glioma undergoing tumor resection: a retrospective cohort study. J Neurosurg Anesthesiol. 2020;32(3):227-233.
15. Oh TK, Kim HH, Jeon YT. Retrospective analysis of 1-year mortality after gastric cancer surgery: total intravenous anesthesia versus volatile anesthesia. Acta Anesthesiol Scand. 2019;63(9):1169-1177.
16. Sessler DI, Pei L, Huang Y, et al. Recurrence of breast cancer after regional or general anesthesia: a randomised controlled trial. Lancet. 2019;394(10211):1807-1815.
17. Zhang L, Wang N, Zhou S, Ye W, Jing G, Zhang M. Propofol induces proliferation and invasion of gallbladder cancer cells through activation of Nrf2. J Exp Clin Cancer Res. 2012;31:66.
18. Meng C, Song L, Wang J, Li D, Liu Y, Cui X. Propofol induces proliferation partially via downregulation of p53 protein and promotes migration via activation of the Nrf2 pathway in human breast cancer cell line MDA-MB-231. Oncol Rep. 2017;37(2):841-848.
19. Miao Y, Zhang Y, Wan H, Chen L, Wang F. GABA-receptor agonist, propofol induces injection of colon carcinoma cells. Biomed Pharmacother. 2010;64(9):583-588.
20. Li Q, Zhang L, Han Y, Jiang Z, Wang Q. Propofol reduces MMPs expression by inhibiting NF-kappaB activity in human MDA-MB-231 cells. Biomed Pharmacother. 2012;66(1):52-56.
21. Wu KC, Yang ST, Hsia TC, et al. Suppression of cell invasion and migration by propofol are involved in down-regulating matrix metalloproteinase-2 and p38 MAPK signaling in AS549 human lung adenocarcinoma epithelial cells. Anticancer Res. 2012;32(11):4833-4842.
22. Zhang J, Zhang D, Wu GQ, Feng ZY, Zhu SM. Propofol inhibits the adhesion of hepatocellular carcinoma cells by upregulating microRNA-199a and downregulating MMP-9 expression. Hepatobiliary Pancreat Dis Int. 2013;12(3):305-309.
23. Zhang F, Wang C, Cui Y, et al. Effects of propofol on several membrane characteristics of cervical cancer cell lines. Cell Physiol Biochem. 2016;40(4):172-182.
24. Chen X, Li K, Zhao G. Propofol inhibits HeLa cells by impairing autophagic flux via AMP-activated protein kinase (AMPK) activation and endoplasmic reticulum stress regulated by calcium. Med Sci Monit. 2018;24:2339-2349.
25. Khan AA, Alanazi AM, Jabeen M, Chauhan A, Abdelhameed AS. Design, synthesis and in vitro anticancer evaluation of a stearic acid-based ester conjugate. Anticancer Res. 2013;33(6):2517-2524.
26. Xu YB, Du QH, Zhang MY, Yun P, He CY. Propofol suppresses proliferation, invasion and angiogenesis by down-regulating ERK-VEGF/MMP-9 signaling in Eca-109 esophageal squamous cell carcinoma cells. Eur Rev Med Pharmacol Sci. 2013;17(18):2486-2494.
27. Sen Y, Xiyan H, Yu H. Effect of thoracic paraspinal block-propofol intravenous general anesthesia on VEGF and TGF-beta in patients recovering radical resection of lung cancer. Medicine. 2019;98(47):e18088.
28. Aaura AI, Flood G, Gallagher HC, Buggy DJ. Differential effects of serum from patients administered distinct anaesthetic techniques on apoptosis in breast cancer cells in vitro: a pilot study. Br J Anaesth. 2014;113(suppl 1):i63-i67.
29. Xu YJ, Li SY, Cheng Q, et al. Effects of anesthesia on proliferation, invasion and apoptosis of LoVo colon cancer cells in vitro. Anaesthesia. 2016;71(2):147-154.
30. Zhang D, Zhou X-H, Zhang J, et al. Propofol promotes cell apoptosis via inhibiting HOTAIR mediated mTOR pathway in cervical cancer. Biochem Biophys Res Commun. 2015;468(4):561-567.
31. Xu W, Zheng J, Bie S, et al. Propofol inhibits Wnt signaling and exerts anticancer activity in glioma cells. Oncol Lett. 2018;16(1):402-408.
32. Xing SG, Zhang KJ, Qu JH, Ren YD, Luan Q. Propofol induces apoptosis of non-small cell lung cancer cells via ERK1/2-dependent upregulation of PUMA. Eur Rev Med Pharmacol Sci. 2018;22(13):4341-4349.
33. Zhang Z, Zang M, Wang S, Wang C. Effects of propofol on human cholangiocarcinoma and the associated mechanisms. Exp Ther Med. 2017;19(1):472-478.
34. Kang FC, Wang SC, So EC, et al. Propofol may increase caspase and MAPK pathways, and suppress the Akt pathway to induce apoptosis in MA10 mouse Leydig tumor cells. Oncol Rep. 2019;41(6):3565-3574.
35. Chen X, Wu Q, Sun P, Zhao Y, Zhu M, Miao C. Propofol disrupts aerobic glycolysis in colorectal cancer cells via inactivation of the NMDAR-CAMKII-ERK pathway. Cell Physiol Biochem. 2018;46(2):492-504.
36. Chen F, Li M, Zhu X. Propofol suppresses proliferation and migration of papillary thyroid cancer cells by down-regulation of IncRNA ANRIL. Exp Mol Pathol. 2019;107:68-76.
37. Chen L, Wan Y, Liu Y, Li T. Propofol inhibits biological functions of leukaemia stem and differentiated cells through suppressing Wnt/beta-catenin and Akt/mTOR. Clin Exp Pharmacol Physiol. 2020;47(1):127-134.
38. Yang C, Gao J, Yan N, et al. Propofol inhibits the growth and survival of gastric cancer cells in vitro through the upregulation of ING3. Oncol Rep. 2017;37(1):587-593.
39. Gao C, Ren C, Liu Z, Zhang L, Tang R, Li X. GAS5, a FoxO1-activated long noncoding RNA, promotes propofol-induced oral squamous cell carcinoma apoptosis by regulating the mir-1297-5GSK3beta axis. Artif Cells Nanomod Biotechnol. 2019;47(1):3985-3993.
40. Du Q, Liu J, Zhang X, et al. Propofol inhibits proliferation, migration, and invasion but promotes apoptosis by regulation of Sox4 in endometrial cancer cells. Braz J Med Biol Res. 2018;51(4):e6803.
41. Su Z, Liu HL, Qi B, Liu Y. Effects of propofol on proliferation and apoptosis of cardia cancer cells via MAPK/ERK signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24(1):428-433.
42. Ashrafzadeh M, Ahmadi Z, Farkhondeh T, Samarghandian S. Anti-tumor activity of propofol: a focus on MicroRNAs. Eur Rev Med Pharmacol Sci. 2020;24(1):428-433.
43. Su Z, Hou X, Wen QP. Propofol induces apoptosis of epithelial ovarian cancer cells by upregulation of microRNA let-7i expression. Exp J Gynaecol Oncol. 2014;35(6):688-691.
44. Wang ZT, Gong HY, Zheng F, Liu DJ, Dong TL. Propofol suppresses proliferation and invasion of pancreatic cancer cells by upregulating microRNA-133a expression. Genet Mol Res. 2015;14(3):7529-7537.
45. Gong T, Ning X, Deng Z, et al. Propofol-induced miR-219-5p inhibits growth and invasion of hepatocellular carcinoma through suppression of GPC3-mediated Wnt/beta-catenin signalling activation. J Cell Biochem. 2019;120(10):16934-16945.
46. Ye Z, Jingzhong L, Yangbo L, Lei C, Jiandong Y. Propofol inhibits proliferation and invasion of osteosarcoma cells by regulation of microRNA-143 expression. Oncol Res. 2013;21(4):201-207.
47. Huang X, Teng Y, Yang H, Ma J. Propofol inhibits invasion and growth of ovarian cancer cells via regulating miR-9/NF-kappaB signal. *Braz J Med Biol Res*. 2016;49(12):e5717.

48. Zhang W, Wang Y, Zhu Z, Zheng Y, Song B. Propofol inhibits proliferation, migration and invasion of gastric cancer cells by up-regulating microRNA-195. *Int J Biol Macromol*. 2018;120(1):975-984.

49. Ni YJ, Lu J, Zhou HM. Propofol suppresses proliferation, migration and invasion of gastric cancer cells via regulating miR-29/MMP-2 axis. *Eur Rev Med Pharmacol Sci*. 2019;23(19):8606-8615.

50. Zhu F, Li Q, Yang Y, Wang L, Wang J. Propofol suppresses proliferation, migration, invasion and promotes apoptosis by upregulating microRNA-140-5p in gastric cancer cells. *Onco Targets Ther*. 2019;12:10129-10138.

51. Yang N, Liang Y, Yang P, Yang T, Jiang L. Propofol inhibits lung cancer cell viability and induces cell apoptosis by upregulating microRNA-486 expression. *Braz J Med Biol Res*. 2017;50(1):e5794.

52. Liu WZ, Liu N. Propofol inhibits lung cancer A549 cell growth and epithelial-mesenchymal transition process by upregulation of microRNA-1284. *Onco Res*. 2018;27(1):1-8.

53. Yu X, Gao Y, Zhang F. Propofol inhibits pancreatic cancer proliferation and metastasis by up-regulating miR-328 and down-regulating ADAM8. *Basic Clin Pharmacol Toxicol*. 2019;125(3):271-278.

54. Li Y, Dong W, Yang H, Xiao G. Propofol suppresses proliferation and metastasis of colorectal cancer cells by regulating miR-124-3p/1/AKT3. *Biotechnol Lett*. 2020;42(3):493-504.

55. Liu SQ, Zhang JL, Li ZW, Hu ZH, Liu Z, Li Y. Propofol inhibits proliferation, migration, invasion and promotes apoptosis through down-regulating miR-374a in hepatocarcinoma cell lines. *Cell Physiol Biochem*. 2018;49(6):2099-2110.

56. Wang ZT, Gong HY, Zheng F, Liu DJ, Yue XQ. Propofol suppresses proliferation and invasion of gastric cancer cells via downregulation of microRNA-221 expression. *Genet Mol Res*. 2015;14(3):8117-8124.

57. Liu Z, Zhang J, Hong G, Quan J, Zhang L, Yu M. Propofol inhibits growth and invasion of pancreatic cancer cells through regulation of the miR-21/Slug signaling pathway. *Am J Transl Res*. 2016;8(10):4120-4133.

58. Yu B, Gao W, Zhou H, et al. Propofol induces apoptosis of breast cancer cells by downregulation of miR-24 signal pathway. *Cancer Biomark*. 2018;21(3):513-519.

59. Du Q, Zhang X, Zhang X, Wei M, Xu H, Wang S. Propofol inhibits proliferation and epithelial-mesenchymal transition of MCF-7 cells by suppressing miR-21 expression. *Artif Cells Nanomed Biotechnol*. 2019;47(1):1265-1271.

60. Sun H, Gao D. Propofol suppresses growth, migration and invasion of A549 cells by down-regulation of miR-372. *BMC Cancer*. 2018;18(1):1252.

61. Morello M, Miniaci Chi V, de Candia P, et al. Large oncosomes mediate intercellular transfer of functional microRNA. *Cell Cycle*. 2013;12(22):3526-3536.

62. Zhang J, Shan W-F, Jin T-T, et al. Propofol exerts anti-hepato-cellular carcinoma by microvesicle-mediated transfer of miR-142-3p from macrophage to cancer cells. *J Transl Med*. 2014;12:279.

63. Buschmann D, Brandes F, Lindemann A, et al. Propofol and sevoflurane differentially impact microRNAs in circulating extracellular vesicles during colorectal cancer resection: a pilot study. *Anesthesiology*. 2020;132(1):107-120.

64. Chen Q, Zhu C, Jin Y. The oncogenic and tumor suppressive functions of the long noncoding RNA MALAT1: an emerging controversy. *Front Genet*. 2020;11:93.

65. Zhang YF, Li CS, Zhou Y, Lu XH. Effects of propofol on colon cancer metastasis through STAT3/HOTAIR axis by activating WiFi-1 and suppressing Wnt pathway. *Cancer Med*. 2020;9(5):1842-1854.

66. Ren YL, Zhang W. Propofol promotes apoptosis of colorectal cancer cells via alleviating the suppression of IncRNA HOXA11-AS on miRNA let-7i. *Biochem Cell Biol*. 2020;98(2):90-98.

67. Zhang YF, Li CS, Zhou Y, Lu XH. Propofol facilitates cisplatin sensitivity via IncRNA MALAT1/miR-30e/AT5G axis through suppressing autophagy in gastric cancer. *Life Sci*. 2020;244:117280.

68. Li X, He S, Ma B. Autophagy and autophagy-related proteins in cancer. *Mol Cancer*. 2020;19(1):12.

69. Barnard RA, Regan DP, Hansen RJ, Maycotte P, Thorburn A, Gustafson DL. Autophagy inhibition delays early but not late-stage metastatic disease. *J Pharmacol Exp Ther*. 2016;358(2):282-293.

70. Guo YJ, Xia B, White E. Autophagy-mediated tumor promotion. *Cell*. 2013;155(6):1216-1219.

71. White E. Deconvoluting the context-dependent role for autophagy in cancer. *Nat Rev Cancer*. 2012;12(6):401-410.

72. Fung C, Lock R, Gao S, Salas E, Debnath J. Induction of autophagy during extracellular matrix detachment promotes cell survival. *Mol Biol Cell*. 2008;19(3):797-806.

73. MacIntosh RL, Timpson P, Thorburn J, Anderson K, Thorburn A, Ryan KM. Inhibition of autophagy impairs tumor cell invasion in an organotypic model. *Cell Cycle*. 2012;11(10):2022-2029.

74. Peng Y-F, Shi Y-H, Ding Z-B, et al. Autophagy inhibition suppresses pulmonary metastasis of HCC in mice via impairing anoikis resistance and colonization of HCC cells. *Autophagy*. 2013;9(12):2056-2068.

75. Li H, Lu Y, Pang Y, Li M, Cheng X, Chen J. Propofol enhances the cisplatin-induced apoptosis on cervical cancer cells via EGFR/JAK2/STAT3 pathway. *Biomed Pharmacother*. 2017;86:324-333.

76. Sun Y, Peng YB, Ye LL, Ma LX, Zou MY, Cheng ZG. Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA374a/forkhead box O1 signaling axis. *Mol Med Rep*. 2020;21(3):1471-1480.

77. Wang P, Chen J, Mu LH, Du QH, Niu XH, Zhang MY. Propofol inhibits invasion and enhances paclitaxel-induced apoptosis in ovarian cancer cells through the suppression of the transcription factor slug. *Eur Rev Med Pharmacol Sci*. 2013;17(13):1722-1729.

78. Du QH, Xu YB, Zhang MY, Yun P, He CY. Propofol induces apoptosis and increases gemcitabine sensitivity in pancreatic cancer cells in vitro by inhibition of nuclear factor-kappaB activity. *World J Gastroenterol*. 2013;19(33):5485-5492.

79. Scheel C, Weinberg RA. Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? *Int J Cancer*. 2011;129(10):2310-2314.

80. Qian J, Shen S, Chen W, Chen N. Propofol reversed hypoxia-induced docetaxel resistance in prostate cancer cells by preventing epithelial-mesenchymal transition by inhibiting hypoxia-inducible factor 1alpha. *Biomed Res Int*. 2018;2018:4174232.

81. Yang N, Liang Y, Yang P, Ji F. Propofol suppresses LPS-induced nuclear accretion of HIF-1alpha and tumor aggressiveness in non-small cell lung cancer. *Onco Rep*. 2017;37(5):2611-2619.

82. Cui WY, Liu Y, Zhu YQ, Song T, Wang QS. Propofol induces endoplasmic reticulum (ER) stress and apoptosis in lung cancer cell H460. *Tumour Biol*. 2014;35(6):5213-5217.

83. Gao Y, Yu X, Zhang F, Dai J. Propofol inhibits pancreatic cancer progress under hypoxia via ADAM8. *J Hepatobiliary Pancreat Sci*. 2019;26(6):219-226.

84. Li R, Huang Y, Lin J. Distinct effects of general anesthetics on lung metastasis mediated by IL-6/JAK2/STAT3 pathway in mouse models. *Nat Commun*. 2020;11(1):642.

85. Lai H-C, Lee M-S, Lin K-T, et al. Propofol-based total intravenous anesthesia is associated with better survival than desflurane anesthesia in robot-assisted radical prostatectomy. *PLoS ONE*. 2020;15(3):e0230290.

---

**How to cite this article:** Xu Y, Pan S, Jiang W, Xue F, Zhu X. Effects of propofol on the development of cancer in humans. *Cell Prolif*. 2020;53:e12867. [https://doi.org/10.1111/cpr.12867](https://doi.org/10.1111/cpr.12867)